Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on Calix, Raises Price Target to $70

Needham Maintains Buy on Calix, Raises Price Target to $70

Needham analyst Ryan Koontz maintains Calix (NYSE:CALX) with a Buy and raises the price target from $63 to $70.

byBenzinga Newsdesk

October 18, 2022

1 minute read

Needham analyst Ryan Koontz maintains Calix (NYSE:CALX) with a Buy and raises the price target from $63 to $70.

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $17

By Benzinga Newsdesk

March 17, 6:28 AM

HC Wainwright & Co. analyst Robert Burns maintains Prelude Therapeutics (NASDAQ:PRLD) with a Buy and raises the price target from $15 to $17.

PRLD

News

Overview Of Value Stocks In The Communication Services Sector

By Benzinga Insights

May 8, 10:44 AM

Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are…

EEX

Despite Safety Concerns, Analysts Are Bullish On Biogen’s Second Alzheimer’s Candidate

By Vandana Singh

November 30, 2:03 PM

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).

BIIB

Wells Fargo Maintains Overweight on Karuna Therapeutics, Lowers Price Target to $262

By Benzinga Newsdesk

November 4, 12:18 PM

Wells Fargo analyst Jacob Hughes maintains Karuna Therapeutics (NASDAQ:KRTX) with a Overweight and lowers the price target from $264 to $262.

KRTX

Needham Maintains Buy on Calix, Raises Price Target to $70

Related Posts

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $17

Overview Of Value Stocks In The Communication Services Sector

Despite Safety Concerns, Analysts Are Bullish On Biogen’s Second Alzheimer’s Candidate

Wells Fargo Maintains Overweight on Karuna Therapeutics, Lowers Price Target to $262